Skip to main content

Advertisement

SpringerLink
Log in

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

Reliable information on stem cell toxicity and mobilization of stem cells for autologous stem cell transplantation (SCT) after induction treatment with a combination of bendamustine, prednisone and bortezomib (BPV) is missing.

Materials and methods

A retrospective analysis of peripheral blood stem cell mobilization and autologous SCT was performed in 35 patients with MM who had received at least one cycle of a BPV-induction therapy consisting of bendamustine 60 mg/m2 on days 1 and 2, bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 and prednisone 100 mg on days 1, 2, 4, 8 and 11 between October 2008 and May 2014. The mobilization regimen consisted of cyclophosphamide 4 g/m2 and G-CSF (2 × 5 μg/kg). Apheresis was started as soon as peripheral CD34+ counts exceeded 20 × 106/L with a harvest target of 8 × 106 CD34+/kg. The minimal accepted target was 2 × 106 CD34+/kg. The transplantation conditioning therapy consisted of melphalan 200 mg/m2.

Results

A median number of two (range 1–5) BPV cycles were given. The majority of patients (n = 31, 89 %) responded with two sCR, five nCR, 11 VGPR and 13 PR after BPV induction. Three patients had MR, and one SD. Stem cell mobilization and harvest were successful in all patients. In 19 of 35 patients (54 %), a single apheresis was sufficient to reach the target. The median number of aphereses was one (range 1–4), and the median CD34+ cell-count/kg was 13.5 (range 3.2–33.1)  × 106. All patients received an autologous SCT. Engraftment was successful in 34 of 35 patients. The median time to a leukocyte count >l × 109/L was 11 days, and the time to untransfused platelet count of >50 × 109/L was 13 days. Thirty-four patients (97 %) responded after the autologous SCT with 11 sCR, two CR, seven nCR, seven VGPR and seven PR. The progression-free survival at 18 months was 87 %, and overall survival was 92 %.

Conclusion

Stem cell mobilization and autologous SCT are feasible in MM patients who have received BPV-induction therapy .

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Altekruse SF, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W (2011) SEER cancer statistics review 1975–2007, National Cancer Institute, Bethesda. http://www.seercancergov/csr/1975-2007. Accessed March 10, 2011

  • Berdeja JG, Savona MR, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn IW (2013) Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood 122:3193

    Google Scholar 

  • Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321–330

    Article  CAS  PubMed  Google Scholar 

  • Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, Rus C, Bertola A, Giaccone L, Omede P, Musto P, Pileri A (2002) Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87:846–850

    CAS  PubMed  Google Scholar 

  • Breitkreutz I, Lokhorst HM, Raab MS, van der Holt B, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IGH, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H (2007) Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 21:1294–1299

    Article  CAS  PubMed  Google Scholar 

  • Burchardt CA, Brugger W, Maschmeyer G, Kofahl-Krause D, Fischer L, Roller F, Barth J, Rummel MJ (2009) Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III Study of B-R vs. CHOP-R (NHL 1-2003 trial) of the Stil (Study group indolent Lymphomas, Germany). Blood 114:2679

    Google Scholar 

  • Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075–2085

    Article  CAS  PubMed  Google Scholar 

  • Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Garthon G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BGM, San Miguel J, Lonial S, International Myeloma Working Group (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 117:6063–6073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Clark R, Brammer C (1998) Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 22:859–863

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Roussou M, Gavriatopoulou M (2009a) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302–306

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF (2009b) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086–6093

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J-P, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau J-L, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Gavo M, Rajkumar SV, Durie BGM, Miguel JS (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976–4984

    Article  PubMed  Google Scholar 

  • Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854

    Article  CAS  PubMed  Google Scholar 

  • Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473

    Article  CAS  PubMed  Google Scholar 

  • Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 98:736–744

    Article  CAS  PubMed  Google Scholar 

  • Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27:5720–5726

    Article  CAS  PubMed  Google Scholar 

  • Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546–549

    Article  CAS  PubMed  Google Scholar 

  • Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Raikumar SV (2012) Randomized, multicenter phase 2 study (EVOLUTION) of combination of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375–4382

    Article  CAS  PubMed  Google Scholar 

  • Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A (2014) Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol 166:702–710

    Article  CAS  PubMed  Google Scholar 

  • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    Article  CAS  PubMed  Google Scholar 

  • Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weissmann A, Adam Z (2014) Bendamustine-bortezomib-dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985–991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mateos M-V, Oriol A, Rosinol L, de Arriba F, Martin J, Martinez-Lopez J, Echeveste MA, Sarra J, Ramirez G, Ocio EM, Martinez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea A, Blade J, Lahuerta JJ, San Miguel JF (2013) Phase 2 study of bendamustine, bortezomib (velcade) and prednisone (BVP) For newly diagnosed multiple myeloma. Blood 122:2155

    Google Scholar 

  • Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pegourie B, Kolb B, Stoppa AM, Fuzibet J, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traulle C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau J (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752–5758

    Article  CAS  PubMed  Google Scholar 

  • Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase II study. Blood Cancer J 22(3):e162. doi:10.1038/bcl.2013.58

  • Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Guiliani N, Petrucci MT, Must P, Liberati AM, Rossi G, Corradini P, Boccadoro M (2010) Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 28(5):800–807

    Article  CAS  PubMed  Google Scholar 

  • Pönisch W, Mitrou PS, Merkle K-H, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Haematology and Oncology (OSHO). J Cancer Res Clin Oncol 132:205–212

    Article  PubMed  Google Scholar 

  • Pönisch W, Wiesler J, Wagner I, Leiblein S, Edel E, Al-Ali HK, Vucinic V, Hegenbart U, Heiß C, Niederwieser D, Goldschmidt H (2011) Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma. Blood 118:1933

    Google Scholar 

  • Pönisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405–1412

    Article  PubMed  Google Scholar 

  • Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, AL-Ali H, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499–508

    Article  PubMed  Google Scholar 

  • Pönisch W, Holzvogt B, Plötze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann F-A, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D (2014) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol 140:1947–1956

    Article  PubMed  Google Scholar 

  • Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VHJ, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase 2 clinical trial. Leukemia 23:1337–1341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, DeLaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J, Programa para el Estudio y la Terapéutica de las Hemopatías Malignas, Grupo Español de Mieloma (PETHEMA, GEM) group (2012) Superiority of bortezomib, thalidomide, dexamethasone (VTD) as induction pretranplantations therapy in multiple myeloma: a randomized phase III PETHEMA/GEM study. Blood 120:1589–1596

    Article  PubMed  Google Scholar 

  • Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M (2014) Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the intergroupe francophone du myelome. J Clin Oncol 32:2712–2717

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, Goldschmidt H, Rosiñol L, Blade J, Lahueerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine D, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31(26):3279–3287

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest. All authors disclose no financial or personal relationships with other people and organizations.

Author information

Authors and Affiliations

  1. Department of Hematology, University of Leipzig, Johannisallee 32a, 04103, Leipzig, Germany

    Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, Marc Andrea, Thomas Schliwa, Simone Heyn, Georg-Nikolaus Franke, Madlen Jentzsch, Sabine Leiblein, Sebastian Schwind, Thoralf Lange, Vladan Vucinic, Haifa-Katrin AlAli & Dietger Niederwieser

  2. Hospital Torgau, Christianistr. 1, 04860, Torgau, Germany

    Thomas Zehrfeld

  3. HELIOS Vogtland-Klinikum Plauen, Röntgenstraße 2, 08529, Plauen, Germany

    Doreen Hammerschmidt

  4. Medical Care Center Schöneck, Albertplatz 1, 08261, Schöneck, Germany

    Maik Schwarz

  5. Hematology Practise, Theodor-Heuss-Str. 2, 04435, Schkeuditz, Germany

    Thomas Edelmann

  6. Hematology Practise, Biedermannstr. 84, 04277, Leipzig, Germany

    Cornelia Becker & Franz Albert Hoffmann

  7. Hematology Practise, Strümpellstr. 41, Dösen, 04289, Leipzig, Germany

    Andreas Schwarzer

  8. Heinrich-Braun-Hospital, Karl-Keil-Str. 35, 08060, Zwickau, Germany

    Ute Kreibich

  9. Carl-Thiem Klinikum Cottbus, Thiemstraße 111, 03048, Cottbus, Germany

    Kerstin Gutsche

  10. Hospital Zittau, Görlitzer Straße 10, 02763, Zittau, Germany

    Kolja Reifenrath

  11. Georgius-Agricola Hospital Zeitz, Lindenallee 1, 06712, Zeitz, Germany

    Heidrun Schwarzbach

Authors
  1. Wolfram Poenisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madlen Plötze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruno Holzvogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Andrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Schliwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Zehrfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Doreen Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maik Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas Edelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cornelia Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Franz Albert Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Andreas Schwarzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ute Kreibich
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kerstin Gutsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kolja Reifenrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Heidrun Schwarzbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Simone Heyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Georg-Nikolaus Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Madlen Jentzsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Sabine Leiblein
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Sebastian Schwind
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Thoralf Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Vladan Vucinic
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Haifa-Katrin AlAli
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfram Poenisch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poenisch, W., Plötze, M., Holzvogt, B. et al. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. J Cancer Res Clin Oncol 141, 2013–2022 (2015). https://doi.org/10.1007/s00432-015-1984-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-1984-4

Keywords

Search

Navigation